Literature DB >> 15084583

Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies.

Yeong-Gon Choi1, Jae-Il Kim, Yong-Chul Jeon, Seok-Joo Park, Eun-Kyoung Choi, Richard Rubenstein, Richard J Kascsak, Richard I Carp, Yong-Sun Kim.   

Abstract

Transmissible spongiform encephalopathies (TSEs) are transmissible neurodegenerative diseases characterized by the accumulation of an abnormally folded prion protein, termed PrPSc, and the development of pathological features of astrogliosis, vacuolation, neuronal cell loss, and in some cases amyloid plaques. Although considerable structural characterization of prion protein has been reported, neither the method of conversion of cellular prion protein, PrPC, into the pathogenic isoform nor the post-translational modification processes involved is known. We report that in animal and human TSEs, one or more lysines at residues 23, 24, and 27 of PrPSc are covalently modified with advanced glycosylation end products (AGEs), which may be carboxymethyl-lysine (CML), one of the structural varieties of AGEs. The arginine residue at position 37 may also be modified with AGE, but not the arginine residue at position 25. This result suggests that nonenzymatic glycation is one of the post-translational modifications of PrP(Sc). Furthermore, immunostaining studies indicate that, at least in clinically affected hamsters, astrocytes are the first site of this glycation process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084583     DOI: 10.1074/jbc.M400854200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Transmission of prions within the gut and towards the central nervous system.

Authors:  Gianfranco Natale; Michela Ferrucci; Gloria Lazzeri; Antonio Paparelli; Francesco Fornai
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

2.  The small heat shock protein Hsp31 cooperates with Hsp104 to modulate Sup35 prion aggregation.

Authors:  Kiran Aslam; Chai-Jui Tsai; Tony R Hazbun
Journal:  Prion       Date:  2016-11       Impact factor: 3.931

Review 3.  Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis.

Authors:  Shweta Kishor Sonawane; Subashchandrabose Chinnathambi
Journal:  J Mol Neurosci       Date:  2018-07-07       Impact factor: 3.444

4.  Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions.

Authors:  Daniela Saverioni; Silvio Notari; Sabina Capellari; Ilaria Poggiolini; Armin Giese; Hans A Kretzschmar; Piero Parchi
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

5.  Development of monoclonal antibodies specific for glycated prion protein.

Authors:  Eva Dvorakova; Marek Prouza; Olga Janouskova; Martin Panigaj; Karel Holada
Journal:  J Toxicol Environ Health A       Date:  2011

6.  N(ε)-Carboxymethyl Modification of Lysine Residues in Pathogenic Prion Isoforms.

Authors:  Yeong-Gon Choi; Hae-Young Shin; Jae-Il Kim; Eun-Kyoung Choi; Richard I Carp; Yong-Sun Kim
Journal:  Mol Neurobiol       Date:  2015-05-16       Impact factor: 5.590

7.  Anti-prion activity found in beetle grub hemolymph of Trypoxylus dichotomus septentrionalis.

Authors:  Taichi Hamanaka; Keiko Nishizawa; Yuji Sakasegawa; Hiroshi Kurahashi; Ayumi Oguma; Kenta Teruya; Katsumi Doh-Ura
Journal:  Biochem Biophys Rep       Date:  2015-07-17

Review 8.  The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.

Authors:  Parveen Salahuddin; Gulam Rabbani; Rizwan Hasan Khan
Journal:  Cell Mol Biol Lett       Date:  2014-08-20       Impact factor: 5.787

9.  Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.

Authors:  Elizaveta Katorcha; Natallia Makarava; Regina Savtchenko; Alessandra D'Azzo; Ilia V Baskakov
Journal:  PLoS Pathog       Date:  2014-09-11       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.